摘要
目的探讨伊立替康在转移性及进展期食管癌治疗中的疗效及不良反应。方法通过检索Pubmed数据库及万方数据库，对近年关于伊立替康在转移性及进展期食管癌的多项试验及临床观察进行总结。结果伊立替康单药或联合化疗或联合放疗均对食管癌患者有益，且不良反应可耐受。结论以伊立替康为基础的化疗方案成为晚期食管癌患者的新选择。
Objective To study the efficacy and side effects of irinotecan on patients with meta- static and advanced esophageal cancer. Methods By searching Pubmed database and Wanfang data- base, multiple tests and clinical observations of irinotecan on metastatic and advanced esophageal cancer in recent years were summarized. Results The single use of irinotecan, irinotecan combined with chem- otherapy, irinotecan combined with radiotherapy were both beneficial for patients with esop and the adverse effects were tolerable. Conclusions Irinotecan - based chemotherapy choice for patients with metastatic and advanced esophageal cancer. hageal cancer, can be a new
出处
《中国实用医刊》
2014年第9期101-103,共3页
Chinese Journal of Practical Medicine
关键词
食管肿瘤
伊立替康
疗效
Esophageal cancer
Irinotecan
Efficacy
